45,330€
3,94%
Echtzeit-Aktienkurs Intra-Cellular Therapies Inc.
Bid:
Ask:
Echtzeit-Chart der Intra-Cellular Therapies Inc. Aktie
Börsenkurse Intra-Cellular Therapies Inc.
Euro Indikation | - | - | - | - | 45,330€ | 3,94% |
gettex | - | - | - | - | 45,335€ | -0,57% |
Lang & Schwarz | - | - | - | - | 45,375€ | -0,24% |
Nasdaq | - | - | - | - | 49,320$ | 3,14% |
Dollar Indikation | - | - | - | - | 49,407$ | -0,67% |
Börse Frankfurt | - | - | - | - | 45,460€ | 1,75% |
Börse Stuttgart | - | - | - | - | 45,330€ | -0,59% |
Tradegate | - | - | - | - | 45,325€ | -0,35% |
Fundamentaldaten der Intra-Cellular Therapies Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
---|---|---|---|---|---|---|---|
2021 [USD] | 83,80 Mio. | -284,12 Mio. | -284,13 Mio. | -3,50 | - | - | 44,29 |
2020 [USD] | 22,81 Mio. | -226,99 Mio. | -227,01 Mio. | -3,23 | - | - | 159,88 |
2019 [USD] | 0,06 Mio. | -147,72 Mio. | -147,72 Mio. | -2,68 | - | - | 41511,80 |
2018 [USD] | - | -155,13 Mio. | -155,13 Mio. | -2,84 | - | - | - |
2017 [USD] | 0,25 Mio. | -98,83 Mio. | -97,77 Mio. | -2,12 | - | - | 10067,29 |
2016 [USD] | 0,33 Mio. | -115,36 Mio. | -116,43 Mio. | -2,69 | - | - | 5934,25 |
2015 [USD] | 0,09 Mio. | -104,79 Mio. | -104,79 Mio. | -2,91 | - | - | 21411,67 |
2014 [USD] | 0,58 Mio. | -30,69 Mio. | -30,69 Mio. | -1,07 | - | - | 2316,28 |
2013 [USD] | 2,74 Mio. | -26,85 Mio. | -26,87 Mio. | -1,56 | - | - | 367,00 |
Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. |
Profil der Intra-Cellular Therapies Inc. Aktie
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.